References

You can view the abstracts for the references listed below via the National Library of Medicine's PubMed service. Just click the PubMed links. Click here to view the PubMed disclaimer and copyright notice.

  1. Bree RT, Stenson-Cox C, Grealy M, Byrnes L, Gorman AM, Samali A. Cellular longevity: role of apoptosis and replicative senescence.Biogerontology 2002;3:195–206.
    Link to abstract on PubMed
  2. Fulda S, Debatin KM. Apoptosis signaling in tumor therapy. Ann N Y Acad Sci 2004;1028:150–1156.
    Link to abstract on PubMed
  3. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 2005;258:479–517.
    Link to abstract on PubMed
  4. Ziegler U, Groscurth P. Morphological features of cell death. News Physiol Sci 2004;19:124–128.
    Link to abstract on PubMed
  5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
    Link to abstract on PubMed
  6. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798–4811.
    Link to abstract on PubMed
  7. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer. CA Cancer J Clin 2005;55:178–194.
    Link to abstract on PubMed
  8. Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005;23:9394–9407.
    Link to abstract on PubMed
  9. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312–1316.
    Link to abstract on PubMed
  10. Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005;115:2665–2672
    Link to abstract on PubMed
  11. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876–885.
    Link to abstract on PubMed
  12. Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 2005;57:187–215.
    Link to abstract on PubMed
  13. Reed JC. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 2006;3:388–398.
    Link to abstract on PubMed
  14. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 2005;106:408–418.
    Link to abstract on PubMed
  15. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432:307–3315.
    Link to abstract on PubMed
  16. Boogerd W, de Gast GC, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer 2007;109:306–312.
    Link to abstract on PubMed
  17. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 2006;106:1017–1025.
    Link to abstract on PubMed
  18. Kakolyris S, Kalbakis K, Potamianou A, Malamos N, Vamvakas L, Christophillakis C, et al. Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study. Oncology 2006;70:273–279.
    Link to abstract on PubMed
  19. Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE Jr, Loehr SP, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006;65:412–425.
    Link to abstract on PubMed
  20. Lindholm P, Valavaara R, Aitasalo K, Kulmala J, Laine J, Elomaa L, et al. Preoperative hyperfractionated accelerated radiotherapy and radical surgery in advanced head and neck cancer: a prospective phase II study. Radiother Oncol 2006;78:146–151.
    Link to abstract on PubMed
  21. Masi G, Marcucci L, Loupakis F, Cerri E, Barbara C, Bursi S, et al. First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Ann Oncol 2006;17:1249–1254.
    Link to abstract on PubMed
  22. Massacesi C, La Cesa A, Marcucci F, Pilone A, Rocchi MB, Zepponi L, et al. Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. Oncology 2006;70:294–300.
    Link to abstract on PubMed
  23. Mukai M, Oida Y, Tajima T, Kishima K, Ninomiya H, Sato S, et al. Alternating hepatic arterial infusion and systemic chemotherapy for stage IV colorectal cancer with synchronous liver metastasis. Oncol Rep 2006;16:865–870.
    Link to abstract on PubMed
  24. Pittman KB, Olver IN, Koczwara B, Kotasek D, Patterson WK, Keefe DM, et al. Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. Br J Cancer 2006;95:1309–1313.
    Link to abstract on PubMed
  25. Raez LE, Santos ES, Lopes G, Rosado MF, Negret LM, Rocha-Lima, et al. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer 2006;53:347–353.
    Link to abstract on PubMed
  26. Scartozzi M, Falcone A, Pucci F, Braconi C, Pierantoni C, Cavanna L, et al. Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. Tumori 2006;92;384–388.
    Link to abstract on PubMed
  27. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003;22:7414–7430.
    Link to abstract on PubMed
  28. Decaudin D, Marzo I, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy. Int J Oncol 1998;12:141–152.
    Link to abstract on PubMed
  29. Filomenko R, Prevotat L, Rebe C, Cortier M, Jeannin JF, Solary E, et al. Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. Oncogene 2006;25:7635–7645.
    Link to abstract on PubMed
  30. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 2001;20:1063–1075.
    Link to abstract on PubMed
  31. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001;61:1645–1651.
    Link to abstract on PubMed
  32. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 1999;19;274:7987–7992.
    Link to abstract on PubMed
  33. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8:413–450.
    Link to abstract on PubMed
  34. Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, Safa AR. Taxol induces caspase-10-dependent apoptosis. J Biol Chem 2004;279:51057–51067.
    Link to abstract on PubMed
  35. Perkins C, Kim CN, Fang G, Bhalla KN. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res 1998;15;58:4561–4566.
    Link to abstract on PubMed
  36. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22:9030–9040.
    Link to abstract on PubMed
  37. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005;331:851–858.
    Link to abstract on PubMed
  38. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155–162.
    Link to abstract on PubMed
  39. Igney FH, Krammer PH. Death and anti-death: tumor resistance to apoptosis. Nat Rev Cancer 2002;2:277–288.
    Link to abstract on PubMed
  40. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934–2949.
    Link to abstract on PubMed
  41. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420–430.
    Link to abstract on PubMed
  42. Odoux C, Albers A, Amoscato AA, Lotze MT, Wong MK. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel–induced apoptosis in human non-small-cell lung cancer.Int J Cancer. 2002;97:458–465.
    Link to abstract on PubMed
  43. Muhlethaler-Mottet A, Bourloud KB, Auderset K, Joseph JM, Gross N. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP. Oncogene 2004;23:5415–5425.
    Link to abstract on PubMed
  44. Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 2004;64:9105–9114.
    Link to abstract on PubMed
  45. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232–234.
    Link to abstract on PubMed
  46. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002;12:193–213.
    Link to abstract on PubMed
  47. Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest 2005;115:2648–2655.
    Link to abstract on PubMed